Business
LPLDL® Exclusive European License Agreement
LPLDL® Exclusive European License Agreement.
About this update from Optibiotix Health Plc
[{"type":"text","content":"\n \nRNS Number : 7490G OptiBiotix Health PLC 06 March 2018 \n\n6 March 2018\nOptiBiotix Health plc\n(\"OptiBiotix\" or the \"Company\")\n \nLPLDL® Exclusive European License Agreement\n \nOptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has entered into a production and commercialisation agreement with Fine Foods & Pharmaceuticals N.T.M. S.p.A (\"Fine Foods\"). The agreement grants Fine Foods an exclusive license for the production and supply of five formulations containing OptiBiotix's LPLDL® strain in Europe in return for royalty payments and a commitment to maximising the financial return for both parties.\n \nFine Foods is based in Italy and has more than 30 years' experience in the design, development and manufacture of customised formulations and presentations for the pharmaceutical and food supplement industry. With revenues of €120m in 2017, it is one of Europe's largest and fastest growing providers of food supplements and pharmaceutical products, with full GMP certified production facilities and leading pharmaceutical companies such as Pfizer, Bayer, Sanofi etc reported as customers on its website.\n \nFine Foods has an international reputation and world leading expertise in developing unique formulations and presentations containing probiotic strains. Under the terms of the agreement, Fine Foods have an exclusive license to produce and commercialise five new formulations containing OptiBiotix's LPLDL®. One for glucose control, one for reduction of high blood pressure, one for reduction of cholesterol levels and two for the reduction of cardiovascular risk. These proprietary formulations will be marketed in innovative presentations including sachets and 'melt in the mouth' sticks, to their extensive European network in both the pharmaceutical and food supplement industry.\n \nThis agreement is another step in a business to business (B2B) strategy of bringing OptiBiotix's science together with partner's expertise and market reach to create multiple product opportunities to serve consumer healthcare and pharmaceutical markets around the world.\n \nStephen O'Hara, CEO of OptiBiotix, commented: \"We are pleased to announce this exclusive license agreement with Fin...